胸腺肽联合头孢哌酮钠舒巴坦钠治疗慢性阻塞性肺疾病合并肺部感染患者的效果

Effects of Thymosin combined with Cefoperazone sodium and Sulbactam sodium in treatment of chronic obstructive pulmonary disease patients with pulmonary infection

目的:观察胸腺肽联合头孢哌酮钠舒巴坦钠治疗慢性阻塞性肺疾病(COPD)合并肺部感染患者的效果。方法:选取2022年1月至2023年6月该院收治的108例COPD合并肺部感染患者进行前瞻性研究,按随机数字表法将其分为观察组(n=54)与对照组(n=54)。对照组采用注射用头孢哌酮钠舒巴坦钠治疗,观察组在对照组基础上联合注射用胸腺肽治疗。比较两组临床疗效,治疗前后炎性因子[转化生长因子-β(TGF-β)、白细胞介素-6(IL-6)、降钙素原(PCT)]、肺氧合功能指标[呼吸频率(RR)、肺泡-动脉血氧分压差(PA-aO2)、氧合指数(OI)]水平,以及不良反应发生率。结果:观察组治疗总有效率为90.74%(49/54),高于对照组的75.93%(41/54),差异有统计学意义(P<0.05);治疗后,两组TGF-β、IL-6、PCT水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组RR、PA-a O2水平均低于治疗前,且观察组低于对照组,两组OI水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:胸腺肽联合头孢哌酮钠舒巴坦钠治疗COPD合并肺部感染患者可提高治疗总有效率,改善肺氧合功能指标水平,降低炎性因子水平,其效果优于单纯头孢哌酮钠舒巴坦钠治疗。

Objective:To observe effects of Thymosin combined with Cefoperazone sodium and Sulbactam sodium in treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection.Methods:A prospective study was conducted on 108 patients with COPD complicated with pulmonary infection admitted to the hospital from January 2022 to June 2023.According to the random number table method,they were divided into observation group(n=54)and control group(n=54).The control group was treated with Cefoperazone sodium and Sulbactam sodium for injection,while the observation group was treated with Thymosin for injection on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[transforming growth factor-β(TGF-β),interleukin-6(IL-6),procalcitonin(PCT)]and pulmonary oxygenation function indexes[respiratory rate(RR),alveolar-arterial oxygen partial pressure difference(PA-aO2),oxygenation index(OI)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 90.74%(49/54),which was higher than 75.93%(41/54)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TGF-β,IL-6 and PCT in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of RR and PA-aO2 in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the OI of the two groups was higher than that before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Thymosin combined with Cefoperazone sodium and Sulbactam sodium in the treatment of the COPD patients with pulmonary infection can improve the total effective rate of treatment,improve the levels of pulmonary oxygenation function indexes,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Cefoperazone sodium and Sulbactam sodium treatment.